The FINANCIAL -- Astellas Pharma Inc. on March 1 announced that 40 mg XTANDI Tablets and 80 mg XTANDI Tablets received manufacturing and marketing approval in Japan for the treatment of castration-resistant prostate cancer, which add additional dosage forms to the previously available 40 mg XTANDI Capsules. XTANDI (generic name enzalutamide) is an oral androgen receptor inhibitor.
Both the 40 mg XTANDI Tablets and 80 mg XTANDI Tablets are smaller in size than the 40 mg XTANDI Capsules; thus offering a more patient-friendly medication. With the 80 mg tablets, the number of tablets taken each time will also be reduced, according to Astellas Pharma.
Enzalutamide as of January 2018, was being sold in more than 70 countries worldwide. In Japan, XTANDI Capsules were launched in May 2014 for castration-resistant prostate cancer.
Astellas is pleased to deliver XTANDI tablets to patients to further enhance its contributions to the treatment of castration-resistant prostate cancer in the future.
The approval will have no effect on company results in the current fiscal year (ending March 2018).